| Literature DB >> 36101808 |
Ye Lu1, Ying Wang2, Yusong Qiu3, Wenjuan Xuan3.
Abstract
The expression of TTR and apolipoprotein H (APOH) genes and their relationship with prognosis in patients with colorectal cancer (CRC) metastasis by using bioinformatics analysis techniques are explored. The expression profiles of related genes in patients with CRC metastasis are retrieved from the Gene Expression Omnibus (GEO) database. The core genes transthyretin (TTR) and APOH are screened by constructing protein-protein interaction (PPI) network, and the corresponding patient data of 327 patients are extracted and included in the metastasis group. The TTR and APOH genes of 300 patients without CRC metastasis are screened and included in the control group. The relationship between the expression levels of TTR and APOH and the clinicopathological parameters of patients with CRC metastasis is analyzed. Kaplan-Meier survival curve is drawn to observe the influence of overexpression and low expression of TTR and APOH on the prognosis and survival of patients in the metastatic group. Receiver operating characteristic (ROC) curve is drawn to observe the prognostic efficacy of combined TTR and APOH detection in patients with CRC metastasis. The experimental results show that bioassay can confirm the close relationship between TTR, APOH, and patients with CRC metastasis. Regular detection of serum TTR and APOH expression can effectively assess the patient's condition and take measures to improve the prognosis of the patients.Entities:
Mesh:
Substances:
Year: 2022 PMID: 36101808 PMCID: PMC9462980 DOI: 10.1155/2022/1121312
Source DB: PubMed Journal: Contrast Media Mol Imaging ISSN: 1555-4309 Impact factor: 3.009
The baseline data.
| Transfer group ( | Control group ( |
|
| |
|---|---|---|---|---|
| Age (years) | 43.21 ± 9.53 | 44.31 ± 9.31 | −1.460 | 0.145 |
|
| ||||
| Gender | 3.638 | 0.056 | ||
| Male | 198 (60.55%) | 159 (53.00%) | ||
| Female | 129 (39.45%) | 141 (47.00%) | ||
|
| ||||
| BMI (kg/m2) | 23.35 ± 2.47 | 23.19 ± 2.43 | 0.817 | 0.414 |
|
| ||||
| Level of education | 1.248 | 0.523 | ||
| Primary and below | 102 (31.19%) | 87 (29.00%) | ||
| Junior to senior high | 159 (48.62%) | 155 (51.67%) | ||
| University and above | 66 (20.18%) | 58 (19.33%) | ||
Figure 1Upregulated gene.
Figure 2Downregulated gene.
Figure 3Key gene screening.
P values of key genes.
| Gene |
|
|---|---|
| APOH | 3.09 |
| HPD | 2.18 |
| HPX | 3.58 |
| C6 | 4.63 |
| CFHR5 | 5.26 |
| SLC2A2 | 3.63 |
| ITIH1 | 5.32 |
| CP | 4.37 |
| F9 | 3.59 |
| TTR | 4.65 |
| AMBP | 4.21 |
| KING1 | 5.37 |
| F2 | 4.19 |
| CPB2 | 5.18 |
| GC | 4.74 |
| HRG | 4.04 |
| AHSG | 3.48 |
| SERPING1 | 2.18 |
Comparison of the expression of TTR and APOH between the transfer group and the control group.
| Group |
| TTR mRNA | APOH mRNA |
|---|---|---|---|
| Transfer group | 327 | 3.64 ± 1.02 | 5.42 ± 1.21 |
| Control group | 300 | 11.24 ± 3.22 | 9.56 ± 2.10 |
|
| −40.525 | −30.549 | |
|
| <0.001 | <0.001 |
The relationship between TTR and clinicopathological parameters.
| Number ( | High expression | Low expression |
|
| |
|---|---|---|---|---|---|
| Gender | 0.006 | 0.940 | |||
| Male | 357 | 169 (47.34%) | 188 (52.66%) | ||
| Female | 270 | 127 (47.04%) | 143 (52.96%) | ||
|
| |||||
| Age (years) | 0.108 | 0.743 | |||
| ≥40 | 445 | 243 (54.61%) | 202 (45.39%) | ||
| <40 | 182 | 102 (56.04%) | 80 (43.96%) | ||
|
| |||||
| TNM staging | 341.369 | <0.001 | |||
| I ∼ II | 300 | 257 (85.67%) | 43 (14.33%) | ||
| III ∼ IV | 327 | 39 (11.93%) | 288 (88.07%) | ||
|
| |||||
| Tumor diameter (cm) | 241.158 | <0.001 | |||
| ≥4 | 387 | 59 (15.25%) | 328 (84.75%) | ||
| <4 | 240 | 186 (77.50%) | 54 (22.50%) | ||
Figure 4Regression forest plot of TTR and CRC clinicopathological parameters.
The relationship between APOH and clinicopathological parameters.
| Number ( | High expression | Low expression |
|
| |
|---|---|---|---|---|---|
| Gender | 0.556 | 0.456 | |||
| Male | 357 | 176 (49.30%) | 181 (50.70%) | ||
| Female | 270 | 125 (46.30%) | 145 (53.70%) | ||
|
| |||||
| Age (years) | 0.593 | 0.441 | |||
| ≥40 | 445 | 227 (51.01%) | 218 (48.99%) | ||
| <40 | 182 | 99 (54.40%) | 83 (45.60%) | ||
|
| |||||
| TNM staging | 309.678 | <0.001 | |||
| I ∼ II | 300 | 248 (82.67%) | 52 (17.33%) | ||
| III ∼ IV | 327 | 41 (12.54%) | 286 (87.46%) | ||
|
| |||||
| Tumor diameter (cm) | 203.394 | <0.001 | |||
| ≥4 | 387 | 71 (18.35%) | 316 (81.65%) | ||
| <4 | 240 | 182 (75.83%) | 58 (24.17%) | ||
Figure 5Regression forest plot of APOH and CRC clinicopathological parameters.
Figure 6Relationship between TTR expression and prognosis and survival.
Figure 7Relationship between APOH expression and prognosis and survival.
Diagnostic efficiency of each index.
| 95% CI | Sensitivity (%) | Specificity (%) | AUC | Cutoff value | |
|---|---|---|---|---|---|
| The joint detection | 0.861 ∼ 0.958 | 91.10 | 87.40 | 0.926 | — |
| TTR | 0.724 ∼ 0.896 | 78.50 | 72.40 | 0.804 | 4.29 |
| APOH | 0.712 ∼ 0.887 | 75.70 | 74.10 | 0.821 | 6.82 |
Figure 8Prognostic curve of ROC for the patients with CRC metastasis.